Breaking News Instant updates and real-time market news.

SNY

Sanofi

$41.01

-0.04 (-0.10%)

, RHHBY

Roche

$29.99

-0.03 (-0.10%)

11:24
01/11/17
01/11
11:24
01/11/17
11:24

Trump says drug industry is 'getting away with murder'

President-elect Donald Trump said at today's press conference that the drug industry is "getting away with murder" in terms of pricing of drugs in the U.S. Publicly traded companies in the pharma space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

SNY

Sanofi

$41.01

-0.04 (-0.10%)

RHHBY

Roche

$29.99

-0.03 (-0.10%)

NVS

Novartis

$73.23

-0.88 (-1.19%)

PFE

Pfizer

$33.36

-0.085 (-0.25%)

GSK

GlaxoSmithKline

$39.20

-0.14 (-0.36%)

AZN

AstraZeneca

$28.41

-0.3445 (-1.20%)

BMY

Bristol-Myers

$58.27

-1.7101 (-2.85%)

JNJ

Johnson & Johnson

$115.96

-0.2 (-0.17%)

LLY

Eli Lilly

$76.72

0.45 (0.59%)

MRK

Merck

$62.78

2.86 (4.77%)

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 02

    Feb

  • 12

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 29

    Mar

  • 27

    May

SNY Sanofi
$41.01

-0.04 (-0.10%)

01/06/17
RBCM
01/06/17
NO CHANGE
Target $598
RBCM
Outperform
Regeneron price target lowered to $598 from $626 at RBC Capital
RBC Capital analysts Adnan Butt and Michael Yee said that despite the 30-day appeal window and remaining legal process they are removing Praluent from forecasts for Regeneron (REGN) after a pending permanent injunction for the drug was placed against the company and partner Sanofi (SNY) in a court fight brought by Amgen (AMGN). The analysts cut their price target on Regeneron to $598 from $626, but they also believe the news to be a "a clearing event" and would be buyers on any weakness. The analysts keeps their Outperform rating on Regeneron, which is down 7% in early pre-market trading.
01/06/17
JEFF
01/06/17
NO CHANGE
Target $49
JEFF
Buy
Amgen ruling could mean 'blue skies' for Medicines Co., says Jefferies
Jefferies analyst Biren Amin raised his price target for The Medicines Co. (MDCO) to $49 from $43 after the District Court of Delaware ruled in favor of Amgen (AMGN) on the permanent injunction against Sanofi (SNY) and Regeneron's (RENG) Praluent. The ruling should have a favorable read-through to Medicines' inclisiran since the drug is "completely unique to the monoclonal antibody approach" and therefore would not infringe on Amgen's patents, Amin tells investors in a research note titled "Injunction on Sanofi/REGN's Praluent Could Mean Blue Skies for Inclisiran." The analyst raised his inclisiran peak sales estimates to $2.4B in 2027 and keeps a Buy rating on Medicines shares. The stock is up $2.98, or 8%, to $38.50 in pre-market trading.
01/06/17
LEER
01/06/17
NO CHANGE
LEER
Injunction offers more Amgen upside than Regeneron downside, says Leerink
Leerink analyst Geoffrey Porges notes that Amgen (AMGN) prevailed in its suit for a permanent injunction against the sale of Regeneron (REGN)/Sanofi's (SNY) PCSK9 antibody Praluent at the district court level. The analyst believes this injunction offers more upside for Amgen than downside for Regeneron, and points out that this decision affects U.S. Praluent sales only, and is likely to be immediately appealed by Regeneron/Sanofi and potentially granted an extended stay by the Federal Circuit until a final appeal decision is reached.
01/06/17
BERN
01/06/17
NO CHANGE
BERN
Most investors expecting settlement of Praluent fight, says Bernstein
Bernstein analyst Tim Anderson noted the reports that a lower court judge has ruled in favor of Amgen (AMGN) in its ongoing litigation to block Sanofi (SNY) and Regeneron's (REGN) Praluent from being sold in the U.S., though he said it "would be extraordinary" for such a court ruling to actually lead to withdrawal of a product that has been approved and launched. The analyst, who also noted that court order appears to have been delayed 30 days allowing time for an appeal or perhaps a settlement, said that most investors are expecting a settlement. If Praluent were to be blocked in the U.S., the EPS hit to Sanofi would be about 5%, estimates Anderson.
RHHBY Roche
$29.99

-0.03 (-0.10%)

01/03/17
LEER
01/03/17
NO CHANGE
Target $20
LEER
Outperform
Leerink remains bullish on Exelixis in 2017
Leerink analyst Michael Schmidt remains bullish on Exelixis in 2017 and expects continued strong U.S. sales growth of Cabometyx in renal cell carcinoma while several label extension opportunities as well as Roche's (RHHBY) IO strategy for Cotellic are key sources of upside to the current valuation. The analyst reiterated an Outperform rating on Exelixis' stock and raised his price target on the shares to $20 from $16 to reflect his more bullish stance on Cabometyx label extension opportunities, as well as incrementally higher Cotellic profit share estimates following recently announced plans by Roche to initiate additional Phase 3 trials.
01/03/17
RAJA
01/03/17
NO CHANGE
RAJA
Drug price hikes continue unabated, says Raymond James
In a research note titled "Think the Era of Drug Price Increases is Over? Think Again.," Raymond James analyst Christopher Raymond says drug price increases in 2017 are continuing unabated. According to Wolters Kluwer Health, January 1 saw a "sizeable amount of key biotech drug price increases," Raymond tells investors. The price hikes look in-line with previous patterns, or - in the case of Biogen (BIIB) - "measurably more aggressive than norm," the analyst contends. Of the names he follows, Biogen, Acorda Therapeutics (ACOR) and AMAG Pharmaceuticals (AMAG) implemented increases. Raymond also highlights AstraZeneca's (AZN) 5% Lynparza increase and Roche's (RHHBY) "slew of increases" with Actemra up 1.5%, Herceptin up 3%, Pegasys up 5%.
12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/15/16
CANT
12/15/16
NO CHANGE
Target $8
CANT
Overweight
Pacific Biosciences a 'viable takeout target,' says Cantor
Cantor analyst Bryan Brokmeier says Pacific Biosciences' (PACB) shares are oversold after the company announced that Roche (RHHBY) has terminated their IVD-distribution agreement, whereby Roche had exclusive distribution rights of the Sequel into the clinical market. While the analyst acknowledges Roche's termination of the agreement is a clear long-term strategic negative, he says it is not nearly as much as the stock selloff is implying and notes that Pacific Biosciences is now positioned to sell into the clinical sequencing market directly or through other partners. Moreover, Brokmeier believes Pacific Biosciences is now "effectively a viable takeout target" for other companies, with Agilent (A), Bio-Techne (TECH), Illumina (ILMN), PerkinElmer (PKI), Thermo Fisher (TMO), and Roche among potential acquirers. He reiterated an Overweight rating on Pacific Biosciences' stock, but lowered his price target on the shares to $8 from $15.
NVS Novartis
$73.23

-0.88 (-1.19%)

01/06/17
PIPR
01/06/17
NO CHANGE
Target $56
PIPR
Ionis price target raised to $56 after Novartis pact at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer raised his price target on Ionis Pharmaceuticals (IONS) to $56 from $51 after the company announced an agreement with Novartis (NVS) to develop and potentially commercialize two investigational antisense therapies that can potentially lower lipoproteins. Schimmer also cites other recent developments, including FDA approval for Spinraza and a competitor setback for revusiran, for his revision. He keeps an Overweight rating on Ionis shares.
01/04/17
01/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan analyst Richard Vosser downgraded Novartis (NVS) to Neutral from Overweight saying pressures on the company's business are mounting. The pressure from generic erosion in 2017 "remains high" with an estimated $2.3B of sales expected to be lost to generics, said Vosser, who sees "significant downside" to consensus estimates for Novartis. 2. BofA Merrill Lynch analyst Lisa Lewandowski downgraded Philip Morris (PM) to Neutral from Buy and lowered its price target to $96 from $102 citing concerns from the strong U.S. dollar, less impact from an overhaul in U.S. tax policy versus peers, underperformance in combustible tobacco volumes, increasing heat-not-burn competition, a rotation out of defensive/bond proxy assets, and debt convent constraints. 3. Jefferies analyst Andy Barish downgraded Dunkin' Brands (DNKN) to Underperform from Hold, saying he does not believe the company's same-store-sales have broken out above 2% while its international growth has been disappointing. Barish also downgraded Cheesecake Factory (CAKE) to Underperform, citing the 15% post-election rally with no change in fundamentals along with the company's "significant" mall exposure. 4. Evercore ISI downgraded Intuitive Surgical (ISRG) to Hold from Buy and lowered its price target to $690 from $780, with analyst Vijay Kumar saying he expects 2017 to be one of the most challenging for healthcare in general, with the sector facing issues ranging from ACA repeal to border tax reform to interest expense deductibility. 5. Cowen analyst Helane Becker downgraded a number of airline stocks, including United Continental (UAL), JetBlue (JBLU), Alaska Air (ALK) and American Airlines (AAL), to Market Perform from Outperform based on valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/11/17
FBCO
01/11/17
DOWNGRADE
FBCO
Neutral
Novartis downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Matthew Weston downgraded Novartis to Neutral and lowered his price target for the shares to CHF 77 from CHF 92.
01/11/17
01/11/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) downgraded to Market Perform from Outperform at Wells Fargo with analyst Roger Read citing valuation and the absence of an acquisition during the downturn as a way to deliver growth and returns. The window for a deal has likely closed while Exxon trades at a "premium" valuation, Read tells investors in a research note. The analyst lowered his price target range for the shares to $87-$93 from $92-$100. Read's top pick in the International Exploration & Production space is Suncor (SU). 2. AT&T (T) downgraded to Hold from Buy at Deutsche Bank with analyst Matthew Niknam trimming his estimates to reflect weaker margins and slower earnings growth. The analyst notes this is his third downward estimate revision since October. A number of fundamental headwinds, including intensifying competition in wireless/linear video, is likely to pick up in 2017, Niknam tells investors in a research note. He views AT&T's risk/reward as more balanced at current levels and lowered his price target for the shares to $43 from $44. 3. Novartis (NVS) downgraded to Neutral from Outperform at Credit Suisse. 4. Scotts Miracle-Gro downgraded to Hold from Buy at SunTrust with analyst William Chappell citing valuation. 5. Pacific Continental downgraded to Neutral from Buy at DA Davidson and to Market Perform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$33.36

-0.085 (-0.25%)

12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/17
PIPR
01/09/17
NO CHANGE
PIPR
Piper lists Pfizer, Lilly as top 2017 large-cap Pharma picks
Piper Jaffray analyst Richard Purkiss highlights Pfizer (PFE) and Eli Lilly (LLY) as his top large-cap Pharma picks in 2017,saying he prefers "cheaper growth names with limited event risk." With group earnings growth set to halve in 2017 as pipeline momentum stalls, the analyst sees "little likelihood" of sector outperformance. Purkiss calls Merck (MRK) and Johnson & Johnson (JNJ) his least preferred names in large-cap Pharma.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
01/03/17
BRRR
01/03/17
NO CHANGE
Target $15
BRRR
Outperform
Selling OPKO Friday likely a mistake, says Barrington
Investors who sold shares of OPKO Health on Friday's news likely made a mistake, Barrington analyst Michael Petusky tells investors in a research note. The analyst does not believe Pfizer (PFE) would have agreed to the language in the OPKO press release that cited "one or more outliers" if this were not a potentially game-changing issue. Petusky keeps an Outperform rating on shars of OPKO with a $15 price target.
GSK GlaxoSmithKline
$39.20

-0.14 (-0.36%)

10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZN AstraZeneca
$28.41

-0.3445 (-1.20%)

12/19/16
JEFF
12/19/16
UPGRADE
Target $69
JEFF
Buy
Bristol-Myers upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Bristol-Myers Squibb (BMY) to Buy on expectations the company will share with AstraZeneca (AZN) the cytotoxic T-lymphocyte-associated antigen-4 combo opportunity in non-small cell lung cancer. Holford views Bristol shares as attractive valued and upped his price target for the name to $69 from $60.
12/20/16
SBSH
12/20/16
NO CHANGE
Target $151
SBSH
Buy
Citi views Rubraca approval as positive for PARP class
Citi analyst Robyn Karnauskas views the approval of Clovis Oncology's (CLVS) Rubraca as positive for the PARP class. She keeps a Buy rating on TESARO (TSRO) with a $151 price target. TESARO's Niraparib is expected to be approved for second-line maintenance in 2017 while data from its third-line study are expected in the second half of the year. The analyst currently assigns a50% probability to Niraparib in third-line line and 35% market share. Karnauskas notes that Rubraca costs $13,740 for 30 days, below AstraZeneca's (AZN) Lynparza's $11,984. Her model assumes monthly pricing of $10,000 for Niraparib.
12/20/16
LEER
12/20/16
NO CHANGE
LEER
Outperform
Clovis Rubraca approval unlikely to impact TESARO niraparib, says Leerink
Commenting on Clovis' (CLVS) Rubraca accelerated approval by the FDA for the treatment of germline or somatic BRCA-mutated ovarian cancer patients, Leerink analyst Seamus Fernandez says the label appears "fairly broad" and does not restrict use based on platinum sensitivity/resistance. While he believes this current approval is unlikely to impact the initial competitive dynamics for TESARO's (TSRO) niraparib or AstraZeneca's (AZN) Lynparza in second-line maintenance, the analyst points out that data from Rubraca's Phase 3 ARIEL3 trial in this setting is now expected in mid-2017. Despite the earlier readout, Fernandez continues to see niraparib as the ultimate winner in second-line maintenance. He reiterates an Outperform rating on TESARO's shares.
BMY Bristol-Myers
$58.27

-1.7101 (-2.85%)

12/19/16
12/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) and Bayer (BAYRY) were upgraded to Buy from Hold at Jefferies. 2. Costco (COST) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying she sees a "clear path" to accelerating same-store-sales growth in fiscal 2017 as gasoline price deflation headwinds abate and benefits arise from the new co-branded credit card. 3. United Technologies (UTX) upgraded to Outperform from Neutral at Credit Suisse with analyst Julian Mitchell saying he believes consensus estimates are poised to move higher after years of heavy investment spending drive an earnings recovery. 4. ASML (ASML) upgraded to Buy from Neutral at BofA/Merrill with analyst Kai Korschelt saying a recent expert's call indicates progress with Extreme Ultraviolet/EUV lightsource optics & ecosystem and sees improving volume visibility from 2018 forward. 5. Gulfport Energy (GPOR) upgraded to Buy from Neutral at Guggenheim and to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/11/17
JEFF
01/11/17
NO CHANGE
Target $48
JEFF
Buy
Merck filing for Keytruda could disrupt market, says Jefferies
Jefferies analyst Jeffrey Holford views Merck's (MRK) filing for Keytruda plus chemo in first line non-small cell lung cancer as a "positive surprise" that could disrupt market share dynamics in the near term, particularly for Bristol-Myers (BMY). The filing, however, does not materially change Merck's long term outlook, Holford tells investors in a research note. He believes approval risk is high given limited data and keeps an Underperform rating on Merck. The stock is up $1.78 to $61.70 in pre-market trading while Bristol-Myers is down $1.98 to $58.00.
01/11/17
GSCO
01/11/17
NO CHANGE
Target $70
GSCO
Neutral
Goldman sees Merck advantage for Keytruda in first-line NSCLC to be short-lived
Goldman Sachs analyst Jami Rubin said that if Merck's (MRK) chemo combo sBLA is approved, she would expect a "rapid uptake" for Keytruda in the first-line setting given there will be no requirement for PD-L1 testing. However, while Merck may benefit in the near-term in 2017, she is making no change to her 2018 estimates given imminent competition from potentially three other players, adding that she is also making no changes to her estimates for Bristol-Myers (BMY) as she has estimates for first-line non-small cell lung cancer only from 2018. Rubin maintains her Neutral rating and $70 price target on Merck shares.
JNJ Johnson & Johnson
$115.96

-0.2 (-0.17%)

12/20/16
UBSW
12/20/16
NO CHANGE
UBSW
Neutral
Sanofi strategy for Actelion acquisition not clear, says UBS
UBS analyst Jack Scannell provided thoughts on the potential Sanofi (SNY) acquisition of Actelion (ALIOY) after Johnson & Johnson (JNJ) dropped out of the bidding. The reason JNJ backed out was it did not believe it could enhance shareholder value with the deal and Scannell believes the same could be said for Sanofi. He does see a path to accretive earnings in a cash and stock deal and if Sanofi could delever from its EBITDA level within a year. Scannell, however, said the strategic reasons for the deal remain unclear and could raise questions about Sanofi's overall strategy.
01/10/17
PIPR
01/10/17
NO CHANGE
Target $25
PIPR
Overweight
K2M remains 'under-owned and misunderstood,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says K2M Group (KTWO) finished the year solidly after the company preannounced better than expected Q4 results. While the stock should be up today, the company remains "'under-owned and misunderstood," O'Brien tells investors in a research note. K2M over the last few years has quietly taken market share from Johnson & Johnson (JNJ) and Medtronic (MDT) in the $1.4B deformity market, the analyst writes. O'Brien keeps an Overweight rating on the shares with a $25 price target.
12/02/16
GSCO
12/02/16
NO CHANGE
Target $82
GSCO
Buy
Jardiance CV death risk reduction indication a positive for Lilly, says Goldman
Goldman Sachs analyst Jami Rubin said his estimate, and the current consensus estimate, for Jardiance sales assumed that Eli Lilly (LLY) would get a new indication for Jardiance to reduce the risk of cardiovascular death in type 2 diabetes patients, but he still views the news as positive for sentiment given some investor nervousness and the recent solanezumab disappointment. The indication differentiates Jardiance from Johnson & Johnson's (JNJ) Invokana and AstraZeneca's (AZN) Farxiga, adds Rubin, who has a Buy rating and $82 price target on Lilly shares.
LLY Eli Lilly
$76.72

0.45 (0.59%)

12/20/16
FBCO
12/20/16
NO CHANGE
FBCO
Eli Lilly removed from the US Focus List at Credit Suisse
MRK Merck
$62.78

2.86 (4.77%)

01/11/17
JPMS
01/11/17
NO CHANGE
JPMS
Overweight
Keytruda filing a 'distinct positive' for Merck, says JPMorgan
JPMorgan analyst Chris Schott views the acceptance of the Keytruda plus chemo combo supplementary Biologics License Application for priority review as a "distinct positive" for Merck (MRK). The company is increasingly well positioned in first-line lung cancer, Schott tells investors in a research note. The analyst reiterates an Overweight rating on Merck.
01/11/17
BMOC
01/11/17
NO CHANGE
BMOC
FDA decision a significant boost for Merck, says BMO Capital
BMO Capital analyst Alex Arfaei says that the FDA's acceptance and priority review of Merck's Keytruda+chemo in first line non-small cell lung cancer "is a positive surprise." and "represents significant upside" for the company. The analyst thinks that Keytruda's market share in first line non-small cell lung cancer can reach about 80%-85%, up from about 25% now. He continues to identify Merck as his top pick.

TODAY'S FREE FLY STORIES

MCD

McDonald's

, HAL

Halliburton

09:41
01/23/17
01/23
09:41
01/23/17
09:41
Options
Unusually active option classes on open January 23rd »

Unusual total active…

MCD

McDonald's

HAL

Halliburton

DXJ

WisdomTree Japan Hedged Equity Fund

STX

Seagate

$36.47

0.13 (0.36%)

MET

MetLife

PBR

Petrobras

TWTR

Twitter

BABA

Alibaba

AKS

AK Steel

INTC

Intel

$36.94

0.37 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 26

    Jan

  • 02

    Feb

  • 09

    Feb

  • 21

    Feb

  • 28

    Feb

  • 05

    Mar

  • 13

    Jun

FNSR

Finisar

$30.00

-0.89 (-2.88%)

09:39
01/23/17
01/23
09:39
01/23/17
09:39
Recommendations
Finisar analyst commentary  »

Finisar shares defended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

TRGP

Targa Resources

09:37
01/23/17
01/23
09:37
01/23/17
09:37
Syndicate
Targa Resources 8M share Spot Secondary priced at $57.65 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HAL

Halliburton

09:37
01/23/17
01/23
09:37
01/23/17
09:37
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

QCOM

Qualcomm

$62.88

-1.56 (-2.42%)

09:36
01/23/17
01/23
09:36
01/23/17
09:36
Technical Analysis
Qualcomm accelerates to the downside, breaks intraday support »

Shares were last at $57,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 07

    Feb

  • 13

    Mar

UA

Under Armour

, DOW

Dow Chemical

09:35
01/23/17
01/23
09:35
01/23/17
09:35
Hot Stocks
President Trump speaks of 'substantial' border tax »

President Trump, while…

UA

Under Armour

DOW

Dow Chemical

TSLA

Tesla

$244.73

0.97 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

  • 31

    Jan

  • 02

    Feb

AMZN

Amazon.com

$808.33

-0.71 (-0.09%)

09:35
01/23/17
01/23
09:35
01/23/17
09:35
Periodicals
Amazon considers paid search on Alexa, Business Insider reports »

Amazon is considering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 28

    Feb

HAL

Halliburton

09:35
01/23/17
01/23
09:35
01/23/17
09:35
Hot Stocks
Halliburton says had Q4 costs from more head count reductions »

Says cut more jobs in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

09:35
01/23/17
01/23
09:35
01/23/17
09:35
General news
Trump underscored his pro-business bona fides with CEOs »

Trump underscored his…

FNSR

Finisar

$30.00

-0.89 (-2.88%)

09:33
01/23/17
01/23
09:33
01/23/17
09:33
Technical Analysis
Finisar breaks down sharply, bearish pattern now active »

The stock is down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

CPN

Calpine

09:32
01/23/17
01/23
09:32
01/23/17
09:32
Downgrade
Calpine rating change  »

Calpine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

  • 28

    Feb

NRG

NRG Energy

09:32
01/23/17
01/23
09:32
01/23/17
09:32
Upgrade
NRG Energy rating change  »

NRG Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

PEBO

Peoples Bancorp

$31.43

0.5 (1.62%)

09:31
01/23/17
01/23
09:31
01/23/17
09:31
Hot Stocks
Peoples Bancorp Chief Commercial Banking Officer Daniel McGill resigns »

Peoples Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

FNSR

Finisar

$30.00

-0.89 (-2.88%)

, OCLR

Oclaro

$9.37

-0.11 (-1.16%)

09:30
01/23/17
01/23
09:30
01/23/17
09:30
Hot Stocks
Finisar lower after Rosenblatt uncovers Huawei disqualification »

Rosenblatt analyst Jun…

FNSR

Finisar

$30.00

-0.89 (-2.88%)

OCLR

Oclaro

$9.37

-0.11 (-1.16%)

LITE

Lumentum

$35.15

0.05 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 22

    Feb

  • 16

    Mar

09:30
01/23/17
01/23
09:30
01/23/17
09:30
General news
Treasury Action: Treasury supply is heavy this week »

Treasury Action: Treasury…

HAL

Halliburton

09:29
01/23/17
01/23
09:29
01/23/17
09:29
Hot Stocks
Halliburton sees 2017 CapEx $1B »

Says considering various…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CFG

Citizens Financial

09:28
01/23/17
01/23
09:28
01/23/17
09:28
Upgrade
Citizens Financial rating change  »

Citizens Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

09:28
01/23/17
01/23
09:28
01/23/17
09:28
Upgrade
SunTrust rating change  »

SunTrust upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMTX

SMTC Corp.

09:27
01/23/17
01/23
09:27
01/23/17
09:27
Hot Stocks
SMTC Corp. CEO Sushil Dhiman resigns effective February 17 »

SMTC Corporation CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRGP

Targa Resources

09:27
01/23/17
01/23
09:27
01/23/17
09:27
Hot Stocks
Breaking Hot Stocks news story on Targa Resources »

Targa Resources trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

DOW

Dow Chemical

, DD

DuPont

09:26
01/23/17
01/23
09:26
01/23/17
09:26
Periodicals
Breaking Periodicals news story on Dow Chemical, DuPont »

Dow, DuPont granted more…

DOW

Dow Chemical

DD

DuPont

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Jan

  • 02

    Feb

MSI

Motorola Solutions

09:26
01/23/17
01/23
09:26
01/23/17
09:26
Recommendations
Motorola Solutions analyst commentary  »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSX

Diana Shipping

09:25
01/23/17
01/23
09:25
01/23/17
09:25
Hot Stocks
Diana Shipping announces time charter contracts for m/v Los Angeles »

Diana Shipping announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

09:25
01/23/17
01/23
09:25
01/23/17
09:25
General news
A Strong Start for U.S. Producer Sentiment in 2017: »

A Strong Start for U.S.…

HTM

U.S. Geothermal

09:23
01/23/17
01/23
09:23
01/23/17
09:23
Hot Stocks
U.S. Geothermal confirms 2016 guidance and provides 2017 guidance »

U.S. Geothermal confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.